10 Jan Exact Sciences touts early results of new cancer screening tests in the works
A blood test that can identify early cases of lung cancer is showing high levels of accuracy in preliminary tests, Exact Sciences Corp., of Madison, said Monday, and several other cancer tests look promising, as well.
With its Cologuard DNA stool test for colorectal cancer used last year by nearly 250,000 Americans, Exact Sciences says it is collaborating with Mayo Clinic on seven more products to screen for cancer.
Exact will release an update on its product pipeline at the J.P. Morgan Healthcare Conference in San Francisco on Thursday but made the presentation public on Monday. The conference — an annual event that draws thousands of life science professionals, venture capitalists and investment bankers — is considered one of the most important biotech gatherings of the year.
Sorry, the comment form is closed at this time.